The Federal Hemp Definition: What Is Enacted and What Has Passed One Chamber

As of August 20, 2026, federal hemp law contains an enacted definition with a 0. 3 percent plant-level threshold, while a separate December 11 provision appears in H. R. 6500, a measure passed by the Senate but not enacted. Those positions are not interchangeable, and the federal position can change after August 20, 2026.

By Cannible Editorial

2026-08-10

As of August 20, 2026, federal hemp law contains an enacted definition with a 0.3 percent plant-level threshold, while a separate December 11 provision appears in H.R. 6500, a measure passed by the Senate but not enacted. Those positions are not interchangeable, and the federal position can change after August 20, 2026. 1 2 3

This article is general information, not individualized legal, medical, business, or compliance advice. Whether any of it applies to a particular person, product or business depends on the facts and on applicable state law; consult a qualified professional.

Start with the enacted definition

Section 781 of Public Law 119-37 amends the federal definition of hemp to cover the plant Cannabis sativa L. and any part of it, including seeds, derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers. The enacted text sets the general limit at a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of not more than 0.3 percent on a dry-weight basis. 1 2

The enacted definition also includes industrial hemp. In the same text, industrial hemp covers plants grown for stalk, fiber, grain, oil, cake, nuts, hulls, and other non-cannabinoid materials from the plant or its seeds. It also covers certain microgreens and edible hemp leaf products from immature plants, qualifying research plants that do not enter commerce, and viable seed produced solely for those purposes. 1

The definition distinguishes industrial hemp from a hemp-derived cannabinoid product. The latter is a product derived from hemp other than industrial hemp, containing cannabinoids in any form and intended for human or animal use through methods such as inhalation, ingestion, or topical application. 1

The enacted text uses different thresholds for different products

The enacted text excludes viable seeds from a Cannabis sativa L. plant that exceeds 0.3 percent total tetrahydrocannabinols, including tetrahydrocannabinolic acid, in the plant on a dry-weight basis. That is a plant-based threshold, distinct from the limit applied to certain finished products. 1

For intermediate hemp-derived cannabinoid products, the enacted text excludes products containing cannabinoids that the plant cannot naturally produce, as well as cannabinoids that the plant can naturally produce but that were synthesized or manufactured outside the plant. It also excludes an intermediate product containing more than 0.3 percent combined total of tetrahydrocannabinols, including tetrahydrocannabinolic acid, and other cannabinoids that have similar effects, or are marketed as having similar effects, on humans or animals as tetrahydrocannabinol. 1

The intermediate-product category is broad. It includes a product not yet in the final form intended for human or animal use, and a powder, liquid, tablet, oil, or other form intended or marketed to be mixed, dissolved, formulated, or added to another substance before administration or consumption. The enacted text also excludes an intermediate product marketed or sold as a final product or directly to an end consumer for personal or household use. 1

For final hemp-derived cannabinoid products, the enacted text excludes the same categories of non-naturally produced or externally synthesized cannabinoids. It also excludes a final product containing greater than 0.4 milligrams per container, in combined total, of tetrahydrocannabinols, including tetrahydrocannabinolic acid, and other cannabinoids with similar or similarly marketed effects as tetrahydrocannabinol. 1

The 0.4-milligram limit is measured per container. The enacted text defines the container as the innermost wrapping, packaging, or vessel directly contacting the final product and enclosing it for retail sale, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. Bulk shipping containers and outer wrappings that are not essential to the final retail delivery or sale are excluded from that definition. 1

The enacted text separately excludes a drug that is the subject of an application approved under specified provisions of the Federal Food, Drug, and Cosmetic Act. The evidence supplied here does not describe how any particular product would be classified under the full federal framework or under a particular state’s rules. 1

Why the definition is contested

The dispute is structurally difficult because the enacted text does not use one measurement for every product. It combines a 0.3 percent dry-weight threshold for the plant and certain intermediate products with a 0.4-milligram-per-container threshold for certain final products. It also addresses whether cannabinoids can be naturally produced by the plant and whether naturally producible cannabinoids were synthesized or manufactured outside it. 1

The enacted text assigns the Secretary of Health and Human Services a role in determining which other cannabinoids have effects, or are marketed as having effects, similar to tetrahydrocannabinol. It also directs the Food and Drug Administration, within 90 days of enactment, to publish lists concerning naturally producible cannabinoids, naturally occurring tetrahydrocannabinol-class cannabinoids, other cannabinoids with similar or similarly marketed effects, and additional information about the term container. 1

Delta-8 THC illustrates why cannabinoid categories can raise practical questions without changing what the enacted text says. The supplied federal consumer material describes delta-8 THC as a naturally occurring cannabinoid found in significant amounts only at low levels, with concentrated amounts typically manufactured from hemp-derived cannabidiol. It also states that delta-8 THC products have not been evaluated or approved by the FDA for safe use in any context. 4

That federal consumer material reports concerns about variable formulations and labeling, potentially harmful chemicals and contaminants associated with some manufacturing methods, and psychoactive or intoxicating effects. Those safety statements are separate from the enacted statutory definition; they do not by themselves establish whether a particular product falls inside or outside the definition. 4

What the Senate passed on August 8, 2026

On August 8, 2026, the Senate passed H.R. 6500, as amended, by a recorded vote of 90 yeas to 6 nays, with a three-fifths majority required. The recorded question was passage of the bill, and the stated purpose was an act making continuing appropriations and extensions for fiscal year 2027, and for other purposes. 3

The December 11 provision is Section 2019 of that Senate-passed measure, not statutory text and not law. As described in the supplied text, Section 2019 would provide that, until December 11, 2026, the amendments made by Section 781 of Division B of Public Law 119-37 would apply only to products containing cannabinoids that are not capable of being naturally produced by the plant. It would also limit that temporary treatment to final products containing those cannabinoids. Because H.R. 6500 has passed one chamber but is not enacted, this provision must not be treated as an amendment currently in force. 2 3

The two Senate roll calls are different questions

Senate roll call vote number 227 occurred on August 8, 2026, at 2:36 a.m. The question was on the motion to table Senate Amendment 6747 to Senate Amendment 6732 to H.R. 6500. The record titled it the Motion to Table Budd Amendment No. 6747, identified the amendment’s purpose as striking Section 2019, and recorded the motion to table as agreed to, 61 yeas to 32 nays. This was a procedural motion, not a vote on final passage and not enactment into law. 5

Senate roll call vote number 228 occurred later on August 8, 2026, at 3:37 a.m. The question was passage of H.R. 6500, as amended. The record reported Bill Passed, 90 yeas to 6 nays, with a three-fifths majority required. That was the final-passage vote in the Senate, but passage by one chamber is not enactment into law. 3

What readers can and cannot conclude

The enacted federal definition is the starting point: it contains the plant-level 0.3 percent threshold, product-specific exclusions, the intermediate-product and final-product categories, and the final-product container threshold. The December 11 provision is instead part of a Senate-passed, unenacted measure. The evidence supplied here does not establish any later action by another chamber, presentment, or enactment of that measure. 1 2 3

Federal rules are not state rules. The evidence supplied here does not provide a state regulator’s hemp definition or state-specific requirements, so it cannot support a conclusion about how any one state treats a product. For a particular product, transaction, or business decision, a qualified professional can evaluate the enacted federal text together with the applicable state rules and the product’s ingredients, form, labeling, and packaging. 1